Background {#Sec1}
==========

Endometrial cancer has the highest incidence in gynecological cancers in Western countries \[[@CR1]\], and the incidence is also increasing in Korea \[[@CR2]\]. Conversely, endometrial cancer has a higher rate of early diagnosis than other gynecologic and solid cancers because symptoms such as irregular bleeding or discharge are easily detected by patients and diagnosis is possible with a simple endometrial curettage or hysteroscopic endometrial biopsy \[[@CR3]\].

According to the National Comprehensive Cancer Network (NCCN) guidelines, early stage endometrial cancer is treated with total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection, with subsequent staging according to the pathologic report. Adjunctive total salpingo-oophorectomy is the standard treatment option, because of the possibility of occult tumor cells in the ovary and the fact that endometrial cancer is advanced by ovarian hormones \[[@CR4], [@CR5]\]. The incidence of ovarian tumors in patients with endometrial cancer is as 7% \[[@CR6]\]. However, surgical menopause caused by removing the ovaries can induce other complications, such as hot flushes, night sweats, vaginal dryness, insomnia, osteoporosis, cardiovascular problem, sexual dysfunction, and cognitive problems that can affect survival and quality of life \[[@CR7]--[@CR11]\]. Exogenous hormone replacement therapy may relieve these menopausal symptoms but can also induce other complications \[[@CR12], [@CR13]\].

Meta-analysis \[[@CR14]\] and other research \[[@CR4], [@CR5], [@CR15], [@CR16]\] on ovarian preservation surgery in young, premenopausal early stage endometrial cancer patients has produced conflicting results. Some studies claim that it is safer to remove the ovaries, although preservation of the ovary generally does not affect patient recurrence or survival. However, in some meta-analyses and reviews, much of the patient data (34.9%) is too old records \[[@CR4]\], therefore, there is a risk of inaccurate medical records. Further, studies included incidentally diagnosed cancer patients who were regarded as having benign disease such as leiomyoma or adenomyosis prior to surgery, and only had hysterectomy planned without salpingo-oophorectomy.

In addition, many patients receive adjuvant treatment such as radiotherapy or chemotherapy after ovarian preserving surgery, which can further damage ovarian functions. These cases do not represent true ovarian preservation or help to reduce the complications of surgical menopause.

This retrospective study compares the survival of early International Federation of Obstetrics and Gynecology (FIGO) stage endometrial cancer patients who have the ovaries preserved with those who had the ovaries removed in a real clinical setting.

Methods {#Sec2}
=======

Medical records of patients with endometrial cancer who were newly diagnosed by endometrial biopsy and treated at National Cancer Center in South Korea between January 2006 and December 2017 were reviewed. A total of 1578 endometrial cancer patients visited our outpatient clinics; however, 497 patients visited only once for counseling or a second opinion, and 439 patients had recurrent disease. Another 103 patients were excluded due to advanced cancer status (FIGO stage III or IV), which resulted in 539 patients who had been diagnosed and treated in our center for early (FIGO stage I or II) endometrial cancer (Fig. [1](#Fig1){ref-type="fig"}). Clinical factors including age at diagnosis, FIGO stage, FIGO grade, histology of the surgically removed tissues, surgical approach method, radicality of hysterectomy, lymph node dissection, and adjuvant chemotherapy and radiotherapy were collected. Fig. 1Study flow chart

Correlations of variables were assessed using the Fisher's exact or Student *t-*test. Five year overall survival (OS) rates and recurrence free survival (RFS) rates were estimated by Kaplan-Meier analysis. The log-rank test was used to compare survival curves. Cox regression analysis was performed to determine the predictive factors for prognosis with hazard ratios (HRs). *P* values \<.05 were considered to be significant. This retrospective study was approved by the institutional review board of our institution (IRB No. NCC2019--0272).

Results {#Sec3}
=======

The 539 patients included 469 in the ovarian removal group and 70 in the ovarian preservation group. The ovarian removal group was significantly older than the ovarian preservation group (*P* \< 0.001). The FIGO stage was earlier in the ovarian preservation group (*P* = 0.0264). Lymph node dissection was more frequently performed in the ovarian removal group. There was no significant difference between the two groups in terms of surgical approach method, radicality of hysterectomy, or the administration of adjuvant chemotherapy or radiotherapy (Table [1](#Tab1){ref-type="table"}). The five-year OS) and RFS) graphs showed no significant differences between ovarian preservation and removal groups (OS: 98.6% vs. 93.0%, *P* = 0.0892, and RFS: 98.5% vs 92.7%, *P* = 0.436, respectively) (Fig. [2](#Fig2){ref-type="fig"}). Adjusted univariate analysis was performed for FIGO stage and patient age. Univariate analysis demonstrated that FIGO grade, histology, and adjuvant chemotherapy were significantly related to RFS and OS. Adjuvant radiotherapy was related to RFS only. Pelvic lymph node dissection was related to OS only. Neither surgical approach nor radicality of hysterectomy were related to RFS or OS. In multivariate analysis, histology and adjuvant chemotherapy were related to OS, and adjuvant chemotherapy and radiotherapy were related to RFS (Table [2](#Tab2){ref-type="table"}). Compared to endometrioid histology, non-endometrioid histology showed relatively low RFS and OS. Ovarian preservation or removal was not related to RFS or OS. Table 1Patient baseline characteristicsVariablesTotalOvary PreservedOvary Removed***N*** = 539***N*** = 70***N*** = 469***P***-valueFIGO Stage IA390 (72.36)60 (85.71)330 (70.36)0.0264 IB126 (23.38)8 (11.43)118 (25.16) II23 (4.27)2 (2.86)21 (4.48)FIGO grade 1293 (54.36)41 (58.57)252 (53.73)0.289 2141 (26.16)21 (30)120 (25.59) 352 (9.65)5 (7.14)47 (10.02) Etc.53 (9.83)3 (4.29)50 (10.66)Histology Endometrioid461 (85.53)66 (94.29)395 (84.22)0.2329 Serous31 (5.75)2 (2.86)29 (6.18) CCC20 (3.71)1 (1.43)19 (4.05) Mucinous/mixed/Undifferentiated/NE/etc.27 (5.01)1 (1.43)26 (5.54)Age (year) mean ± SD52.68 ± 10.4240.94 ± 9.5654.43 ± 9.36\<.0001 \< 3011 (2.04)8 (11.43)3 (0.64)\<.0001 31 \~ 3519 (3.53)13 (18.57)6 (1.28) 36 \~ 4039 (7.24)21 (30)18 (3.84) 40 \~ 4551 (9.46)11 (15.71)40 (8.53) 45\>419 (77.74)17 (24.29)402 (85.71)Approach Laparoscopy395 (73.28)60 (85.71)335 (71.43)0.0366 Laparotomy138 (25.6)10 (14.29)128 (27.29) Etc.6 (1.11)0 (0)6 (1.28)Hysterectomy - radicality A489 (90.72)63 (90)426 (90.83)0.7491 B18 (3.34)2 (2.86)16 (3.41) C27 (5.01)5 (7.14)22 (4.69) Not done5 (0.93)0 (0)5 (1.07)PLND No112 (20.78)23 (32.86)89 (18.98)0.0076 Yes427 (79.22)47 (67.14)380 (81.02)PALND No251 (46.57)51 (72.86)200 (42.64)\<.0001 Yes288 (53.43)19 (27.14)269 (57.36)Adjuvant Chemotherapy No455 (84.42)66 (94.29)389 (82.94)0.0147 Yes84 (15.58)4 (5.71)80 (17.06)Adjuvant radiotherapy No468 (86.83)64 (91.43)404 (86.14)0.2224 Yes71 (13.17)6 (8.57)65 (13.86)*CCC* clear cell carcinoma, *NE* neuroendocrine tumor, *PLND* pelvic lymph node dissection, *PALND* para-aortic lymph node dissectionFig. 2Overall survival and recurrence free survivalTable 2Univariate and multivariate analysis of prognostic factorsvariablesOverall survivalRecurrence Free survivalAdjusted model^**a**^Multivariable^**b**^Adjusted model^**a**^Multivariable^**b**^HR(95% CI)HR(95% CI)HR(95% CI)HR(95% CI)*N* = 539/EVNET = 31*p*-value*N* = 539/EVNET = 31*p*-value*N* = 539/EVNET = 33*p*-value*N* = 539/EVNET = 33*p*-valueOvary preserved1(ref)1(ref) removed2.058 (0.266--15.915)0.48920.865 (0.245--3.052)0.8215FIGO grade 11(ref)**0.0103**1(ref)**0.0339** 22.305 (0.869--6.116)0.09352.418 (1.052--5.556)0.0376 34.215 (1.324--13.42)0.01491.176 (0.255--5.416)0.8355 etc5.102 (1.838--14.162)0.00183.807 (1.465--9.894)0.0061Histology Endometrioid1(ref)**0.0013**1(ref)**0.0006**1(ref)**0.0322** Serous5.333 (2.206--12.892)0.00025.969 (2.437--14.617)\<.00013.548 (1.389--9.062)0.0081 CCC3.381 (0.968--11.806)0.05623.729 (1.064--13.072)0.03973.031 (0.894--10.274)0.075 Mucinous/mixed/Undifferentiated/NE/etc3.212 (0.921--11.196)0.0673.373 (0.963--11.808)0.05721.609 (0.374--6.918)0.5224approach Laparoscopy1(ref)**0.027**1(ref)0.4568 Laparotomy2.298 (1.058--4.992)0.03551.604 (0.765--3.36)0.2106 etc7.88 (0.974--63.726)0.0529--0.9883Hysterectomy - radicality A1(ref)0.25911(ref)0.9624 B--0.99010.598 (0.073--4.913)0.6322 C0.443 (0.091--2.159)0.31390.776 (0.162--3.704)0.7503 Not done6.183 (0.769--49.733)0.0868--0.9887PLND No1(ref)1(ref) Yes0.371 (0.162--0.852)**0.0194**0.549 (0.24--1.256)0.1556PALND No1(ref)1(ref) Yes0.848 (0.407--1.766)0.65931.008 (0.491--2.068)0.9826Adjuvant chemotherapy No1(ref)1(ref)1(ref)1(ref) Yes2.083 (0.969--4.477)**0.0602**0.318 (0.137--0.736)**0.0074**2.864 (1.396--5.873)**0.0041**3.414 (1.649--7.069)**0.0009**Adjuvant radiotherapy No1(ref)1(ref)1(ref) Yes0.659 (0.249--1.744)0.40062.655 (1.163--6.059)**0.0204**3.256 (1.428--7.423)**0.005***CCC* clear cell carcinoma, *NE* neuroendocrine tumor, *PLND* pelvic lymph-node dissection, *PALND* para-aortic lymph node dissection^a^ Adjusted model: adjuted age at diagnosis (≤50 vs \> 50), FIGO stage^b^ Multivariableb: adjuted age at diagnosis (≤50 vs \> 50), FIGO stage

Discussion {#Sec4}
==========

There is no clear consensus on the surgery scale in early stage endometrial cancer patients. Traditionally, total hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection and omentectomy for staging have been performed. According to the NCCN; American Society of Clinical Oncology (ASCO); and European Society for Medical Oncology, European Society of Gynaecological Oncology, and European Society for Radiotherapy & Oncology (ESMO-ESGO-ESTRO) guidelines \[[@CR3], [@CR17], [@CR18]\], ovarian preservation can be considered in pre-menopausal early stage endometrial cancer patients. While oophorectomy removes any occult ovarian metastatic tumor and reduces the ovarian cancer risk, surgical menopausal problems can result.

Previous studies have shown that preserving the ovary does not affect survival in patients with early stage endometrial cancer who are not menopausal, compared with those who have had the ovaries removed \[[@CR4], [@CR5], [@CR14], [@CR15]\]. Previous studies are compared in Table [3](#Tab3){ref-type="table"}. These retrospective studies were conducted in the United States, China, and Korea, conducted mainly with pre-menopausal women as patient groups. Prospective research has been difficult to perform as recruitment of early stage and premenopausal patients has been challenging. Their results showed that in the case of early stage and low FIGO grade, preservation of the ovary did not affect the prognosis of the patient. Recently, a systemic review summarized previous studies, with more than 10,000 cases, and revealed an increase in OS and no shortening of RFS. In the early stages of premenopausal women, ovarian preservation may be a viable treatment option \[[@CR19]\]. The results are similar to ours. However, as previously noted, this research has several limitations, including a large portion of patients with benign disease, the inclusion of patients with adjuvant chemotherapy or radiotherapy after preserving the ovaries \[[@CR5], [@CR16]\], or including patients with old records \[[@CR4]\]. There are many reports of ovarian function deterioration after radiation or chemotherapy in pre-menopausal women \[[@CR20]--[@CR23]\]. These cases demonstrate that preserving the ovaries does not result in maintaining ovarian function, since adjuvant treatment can also induce menopause. Table 3Previous studies about ovarian preservation in endometrial cancer patientsStudyYearCountryPeriodPatientsAgeStageGradeHistologyFollow up period (month)Survival benefitsWright2009USA1988--2004402/286745Ia 64%, Ib 33%, Ic 3%I 79%, II 14%, III 3%endo1--121NSLee2009Korea1993--2005123/−45Ia 74%, Ib 23%, Ic 3%I 70%, II 17%, III 2%Endo (86%)1--125No recur,5-yr OS:98%Sun2012China2002--201034/13245Ia 71%, Ib 22%, Ic 7%I 70%, II 20%, III 10%Endo (97%)27--122NSLee2013Korea1997--2008176/319Ia 89% Ib 5% II 6%I 78% II 18% III 4%endo6--208NSWright2016USA1998--20121121/14527\< 50Ia 89% Ib 8% II 3%I 60% II 27% III 6%endo61, medianNSWang2016China2009--201525/76\< 45Ia 87%, Ib 13%I 75%, II 21%, III 40%Endo (99%)NS*NS* non-specific

Endometrial cancer in premenopausal women has been shown to be hormone related, have early stage, no myometrial invasion, and good prognosis \[[@CR24]\]. If metastatic or synchronous malignancy has not been found in the ovary during surgery, ovarian preservation may be performed; therefore, surgical menopause of the patient is not induced, which may be more beneficial to women's health. We recommend to consider the pathology of the tumor and the necessity of maintaining fertility before surgery.

Although this retrospective study has some limitations, this is the first study in which all patients had been diagnosed with endometrial cancer through preoperative endometrial biopsy, and had ovarian preservation or removal planned in advance of surgery, after confirming no other distant metastasis through computed tomography scan and lab test. Further, a relatively low ratio of patients was administered adjuvant treatment, so this study may serve as a reliable reference for early FIGO stage endometrial cancer. However, this study has limited data about the side effects of each group, especially menopausal problems that occur in the ovarian removal group. Long-term follow-up of adverse effects in postoperative patients may reveal significant differences in patients who have undergone surgical menopause. Second, although a small number of patients received adjuvant treatment after surgery, that treatment was related to survival; consequently, a more accurate group selection process is warranted for future studies.

Cancer survival and life expectancy after diagnosis are increasing, and quality of life issues are becoming more important. It is time forFurther prospective research to confirm whether it is more favorable to remove the ovaries to decrease risk of recurrence or to maintain patient quality of life through ovarian preservation.

Conclusions {#Sec5}
===========

Ovarian preserving surgery in early stage endometrial cancer is a beneficial option for premenopausal patients and is not related to disease recurrence or overall survival rate. More precise stratification analysis is needed to determine which additional groups may safely preserve the ovary.
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